首页>Journal of comparative effectiveness research>Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison.
作者单位：University of Manchester Institute of Cancer Sciences & The Christie NHS Foundation Trust[1]Pfizer Ltd, Walton Oaks, Surrey, UK[2]Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, UK[3]Evidera, Inc., San Francisco[4]Evidera, Inc., Montreal, Canada[5]
换一批
